Rank 35 • Biotech & Discovery
Exscientia
Applies patient-first artificial intelligence platforms to design and develop precision medicines for oncology.
Visit website- Signal Score
- 89.2
- Total raised
- $450M
- Stage
- Public
- Founded
- 2012
- Headquarters
- Oxford, UK
- Region
- Europe
Their signal
Exscientia’s automated precision medicine platform combines machine learning with direct testing on primary human tissues, ensuring designed drug candidates are optimized specifically for real-world patient profiles.
Signal Score 89.2editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.